Bio-Thera Solutions’ BAT1806 receives China NMPA approval
The tocilizumab injection, BAT1806 is a recombinant humanised monoclonal antibody which has been developed to target interleukin-6 receptor (IL-6R). IL-6R specially binds to soluble and membrane-bound IL-6 receptors
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.